KalVista Pharmaceuticals (KALV) Misses Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.80), $0.04 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Bernstein SocGen on Darden Restaurants (DRI): 'Story Intact'
• Kite Realty sells City Center in White Plains for $50 million